Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Discuss Drug Wholesalers’ License Requirements Related to Their “Operational Systems”
October 23, 2017
- MHLW to Discuss Redefinition of Drug “Seals”, Will Revise List of Examples of Seals Included in 1961 Notification
October 23, 2017
- Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
October 23, 2017
- MHLW Advisory Panel to Discuss Pediatric Dosages for Nexium on Nov. 2
October 20, 2017
- Restrictions on Continuous Psychotropic Use Up for Chuikyo Discussions
October 19, 2017
- Price Maintenance Premium, Z2 Reduction Rates under Attack by CEFP Working Group
October 19, 2017
- Chuikyo Discussing Measures to Promote Proper Use of Clozaril for Patients with Treatment-Resistant Schizophrenia
October 19, 2017
- National Database Initiative for Regenerative Medicine Goes Live; Use for Review, Development Eyed
October 18, 2017
- Label Revisions Ordered for 5 APIs, Hitting Slew of Amoxicillin/Chlorhexidine Products
October 18, 2017
- Post-Transplant Patients Added to Careful Use List for Keytruda Label/Guidelines
October 18, 2017
- MHLW to Issue Notification on Revised Format for Package Inserts of Vaccines in Early December
October 18, 2017
- Cabinet Secretariat to Discuss Details of Research on Genome Editing to Be Supported by AMED
October 16, 2017
- MHLW to Purchase Enough Avigan for 44,000 More People, Agreement Expected Nov. 1
October 13, 2017
- Pricing Predictability Could Crumble via Japanese CEA Introduction, Tada Frets at Chuikyo
October 12, 2017
- Premium Rate Threshold Could Preclude CEA-Based Price Raise for Inapplicable Products: Chuikyo Doctor Rep
October 12, 2017
- FPMAJ Chief Trades Barbs with Chuikyo Payer Rep, Says Western-Style HTA Doesn’t Fit Japan’s Unique Market Mechanism
October 12, 2017
- Claims to ADR Victims Relief System Up 277 in FY2016: MHLW
October 12, 2017
- Any CEA-Based Price Adjustment Must Be Limited to Premium Rates: 3 Pharma Groups
October 11, 2017
- MHLW to Issue Basic Guide to PMS for Conditional Early Approval: Drug Review Chief
October 11, 2017
- Japan Needs “Quick and Low-Cost” R&D Setup: Top MD Bureaucrat
October 10, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…